€0.11
+0.02 (+16.92%)
EUR · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where SIGHT.PA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
7 interventional · 1 observational · 1 expanded access · 4 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Bilateral IVT Injection of GS010 at Two Dose Levels in LHON PatientsNCT07303296The primary endpoint will be the BCVA change from baseline to 1.5 years post-treatment in the study eyes.Randomized · Open-label · Treatment | Phase 2 | Recruiting | Genetic: GS010 High dose, GS010 Low dose | Leber Hereditary Optic Disease | 14 | 2028-05-15 | in 635 d | 2026-03-02 |
| Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis PigmentosaNCT03326336The safety and tolerability of escalating doses of GS030-DP administered via a single IVT and repeated light stimulation using GS030-MD in subjects with non-syndromic Retinitis PigmentosaOpen-label · Treatment | Phase 1/2 | Active, not recruiting | Combination product: Gene therapy: GS030-DP AND Medical device: GS030-MD | Non-syndromic Retinitis Pigmentosa | 10 | 2027-10-26 | in 433 d | 2026-03-02 |
| Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 YearNCT03293524results2026-04-16Change From Baseline of the Best Corrected Visual Acuity (BCVA) Reported With Log of the Minimal Angle of Resolution (LogMAR) at 1.5 Years Post-treatment, in the Second Affected/Not-yet Affected EyesRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Genetic: GS010 · Drug: Placebo | Leber Hereditary Optic Neuropathy | 98 | 2024-07-23actual | — | 2026-04-16 |
| RESCUE and REVERSE Long-term Follow-upNCT03406104results2024-01-25Ocular Adverse Events (AEs)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Genetic: GS010 · Other: Sham Intravitreal Injection | Leber Hereditary Optic Neuropathy | 62 | 2022-07-04actual | — | 2026-03-02 |
| REALITY LHON RegistryNCT03295071observationalVisual Function | — | Completed | Other: Patient-reported outcomes (PROs) | Leber Hereditary Optic Neuropathy | 44 | 2020-07-01actual | — | 2026-03-02 |
| Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) PatientsNCT02064569Incidence of local and general adverse events and Serious Adverse EventsOpen-label · Treatment | Phase 1/2 | Completed | Genetic: GS010 | Leber Hereditary Optic Neuropathy | 19 | 2020-06-25actual | — | 2026-03-02 |
| Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months From Onset in LHON Due to the ND4 MutationNCT02652767results2020-01-28Change From Baseline in ETDRS Visual Acuity (Quantitative Score) at Week 48Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: GS010 · Device: Sham Intravitreal Injection | Optic, Atrophy, Hereditary, Leber | 39 | 2018-08-07actual | — | 2026-03-02 |
| Efficacy Study of GS010 for Treatment of Vision Loss From 7 Months to 1 Year From Onset in LHON Due to the ND4 Mutation (REVERSE)NCT02652780results2020-01-23Change From Baseline in ETDRS Visual Acuity (Quantitative Score) at Week 48Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Biological: GS010 · Device: Sham Intravitreal Injection | Optic, Atrophy, Hereditary, Leber | 37 | Jan 2018actual | — | 2026-03-02 |
| EAP_GS010_single PatientNCT03672968expanded access | — | No longer available | Genetic: GS010 | Leber Hereditary Optic Neuropathy (Optic, Atrophy, Hereditary, Leber) | — | — | — | 2026-03-02 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19